Edoxaban ( DrugBank: Edoxaban )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 2 |
| 88 | Chronic thromboembolic pulmonary hypertension | 3 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000026819 | 2016/11/21 | 01/04/2017 | A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients. | A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients. - A RCT of anticoagulant agents for prevention of VTE after THA in elderly or underweight or moderate renal insufficient patients. | osteoarthritis of the hip, osteonecrosis of the femoral head, femoral neck fracture, rheumatoid arthritis, rapidly destructive coxarthropathy, septic arthritis of the hip | Dose: Edoxaban group; Edoxaban 15mg per day Enoxaparin gropu; Enoxaparin 2000 IU per day Intervention period: for 10 days after the surgery | Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 80 | Not selected | Japan |
| 2 | JPRN-UMIN000018101 | 2012/10/01 | 26/06/2015 | Venous thromboembolism after total knee arthroplasty and high tibial osteotomy with / without edxaban: a prospective study | Osteoarthritis, rheumatoid arthritis, osteonecrosis | To determine whether postoperative VTE is present and to evaluate the efficacy and safety of edoxaban for the prevention of patients undergoing TKA, OWHTO, or CWHTO, angiography of the pulmonary artery and deep veins of the lower limbs is performed in all patients on postoperative day 7. Levels of coagulation and fibrinolysis markers are evaluated on the preoperative day and on postoperative days 1, 3, 7, and 14. | Yokohama City University School of Medicine | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 100 | Not selected | Japan |
88. Chronic thromboembolic pulmonary hypertension
Clinical trials : 159 / Drugs : 118 - (DrugBank : 23) / Drug target genes : 13 - Drug target pathways : 53
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2071200098 | 09/04/2021 | 08/02/2021 | Phase III Investigator-Initiated Trial to Investigate Safety and Efficacy of Edoxaban in Patients with Chronic Thromboembolic Pulmonary Hypertension | An Investigator-initiated, multicenter, phase 3, randomized, single-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of edoxaban versus warfarin (Vitamin K antagonist) in subjects with chronic thromboembolic pulmonaty hypertension taking warfarin (Vitamin K antagonist) at baseline - KABUKI | Chronic Thromboembolic Pulmonary Hypertension CTEPH, DOAC, warfarin | Oral administeration of (1) or (2) (1) Edoxaban group - Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily over 60 kg: 60 mg once daily (reduced to 30 mg once daily depending on renal function and concomitant medications) - Warfarin K 1 mg placebo tablets once daily (2)Warfarin group - Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily over 60 kg: 60 mg once daily (reduced to 30 mg once daily depending on renal function and concomitant medications) - Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5) | Abe Kohtaro | NULL | Recruiting | >= 20age old | <= 85age old | Both | 74 | Phase 3 | Japan |
| 2 | NCT04730037 (ClinicalTrials.gov) | April 9, 2021 | 25/1/2021 | Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI) | An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-group Study of Evaluate the Efficacy and Safety of Edoxaban Versus Warfarin (Vitamin K Antagonist) in Subjects With Chronic Thromboembolic Pulmonary Hypertension Taking Warfarin (Vitamin K Antagonist) at Baseline: KABUKI | CTEPH | Drug: Edoxaban;Drug: Warfarin Potassium;Drug: Warfarin Potassium placebo;Drug: Edoxaban placebo | Kyushu University | Daiichi Sankyo Co., Ltd. | Recruiting | 20 Years | 85 Years | All | 74 | Phase 3 | Japan |
| 3 | JPRN-UMIN000018520 | 2016/01/01 | 01/01/2016 | Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertension | CTEPH (chronic thromboembolic pulmonary hypertension) | Initiation of once-daily Edoxaban(60mg) during 6 months after 2 days discontinuation of warfarin | Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 60 | Phase 4 | Japan |